Clinical Cancer Research Targets Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klyushnenkova, E. N.
Right arrow Articles by Alexander, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klyushnenkova, E. N.
Right arrow Articles by Alexander, R. B.
Clinical Cancer Research Vol. 11, 2853-2861, April 15, 2005
© 2005 American Association for Cancer Research


Human Cancer Biology

Identification of HLA-DRB1*1501–Restricted T-cell Epitopes from Prostate-Specific Antigen

Elena N. Klyushnenkova1,2, Jason Link3,4,5, Warren T. Oberle1,2, James Kodak1,2, Cathleen Rich3,4,5, Arthur A. Vandenbark3,4,5 and Richard B. Alexander1,2

Authors' Affiliations: 1 Urology Section, VA Maryland Health Care System, and 2 Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland; 3 Department of Neuroimmunology, Portland VA Medical Center, and Departments of 4 Neurology and 5 Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon

Requests for reprints: Elena N. Klyushnenkova, Department of Surgery, University of Maryland School of Medicine, 10 South Pine Street, Medical School Teaching Facility, Room 4-00A, Baltimore, MD 21201. Phone: 410-706-0755; Fax: 410-706-0311; E-mail: eklyushnenkova{at}smail.umaryland.edu.

The development of immunotherapy for prostate cancer based on the induction of autoimmunity to prostate tissue is very attractive because prostate is not a vital organ beyond the reproductive years. CD4 T cells play an important role in the development of antitumor immune responses, yet the identification of naturally processed MHC Class II–restricted epitopes derived from prostate differentiation antigens has not been described. To facilitate the search for prostate-specific antigen (PSA)–derived MHC class II–restricted peptides, we immunized mice transgenic for HLA-DRB1*1501 with human PSA and showed a robust dose-dependent immune response to the antigen. Screening a library of overlapping 20-mer peptides that span the entire PSA sequence identified two 20-mer peptides, PSA171-190 and PSA221-240, which were responsible for this reactivity. Immunization of DR2b transgenic mice with these peptides induced specific responses to the peptide and whole PSA. Identified peptides were used to stimulate CD4 T cells from HLA-DRB1*1501+ patients with a rare condition, granulomatous prostatitis, and who seem to have a preexisting immune response directed against the prostate gland. We previously showed a linkage of granulomatous prostatitis to HLA-DRB1*1501, suggesting that this disease may have an autoimmune etiology. Peptide-specific CD4 T-cell lines were generated from the peripheral blood of these patients as well as one patient with prostate cancer. These lines also recognized whole, processed PSA in the context of HLA-DRB1*1501. This study will be instrumental in understanding the interaction between circulating self-reactive T cells, organ-specific autoimmunity, and antitumor immune response. The use of these peptides for the immunotherapy of prostate cancer is under investigation.

Key Words: Granulomatous prostatitis • CD4 T lymphocytes • DR2b transgenic mice • HLA-DRB1*1501 • prostate cancer




This article has been cited by other articles:


Home page
J. Immunol.Home page
E. N. Klyushnenkova, D. V. Kouiavskaia, C. A. Berard, and R. B. Alexander
Cutting Edge: Permissive MHC Class II Allele Changes the Pattern of Antitumor Immune Response Resulting in Failure of Tumor Rejection
J. Immunol., February 1, 2009; 182(3): 1242 - 1246.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Penna, S. Amuchastegui, C. Cossetti, F. Aquilano, R. Mariani, N. Giarratana, E. De Carli, B. Fibbi, and L. Adorini
Spontaneous and Prostatic Steroid Binding Protein Peptide-Induced Autoimmune Prostatitis in the Nonobese Diabetic Mouse
J. Immunol., August 1, 2007; 179(3): 1559 - 1567.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.